Peter Castellanos
Neurology with Special Qualifications in Child Neurology · Idaho Falls, IDNPI 1811991474
Payments from drug & device makers
Across 222 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$697
- UCB, Inc.$588
- Neurelis, Inc.$408
- SK Life Science, Inc.$369
- Sunovion Pharmaceuticals Inc.$350
- Supernus Pharmaceuticals, Inc.$228
- plus $981 from 19 others
What the payments were for
- Food & beverage$3,621100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 40 | $697 |
| UCB, Inc. | 38 | $588 |
| Neurelis, Inc. | 25 | $408 |
| SK Life Science, Inc. | 16 | $369 |
| Sunovion Pharmaceuticals Inc. | 39 | $350 |
| Supernus Pharmaceuticals, Inc. | 13 | $228 |
| Jazz Pharmaceuticals Inc. | 11 | $202 |
| Acadia Pharmaceuticals Inc | 8 | $193 |
| Greenwich Biosciences, Inc. | 8 | $144 |
| Ironshore Pharmaceuticals Inc. | 3 | $54 |
| Zogenix Inc. | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 3 | $41 |
| Corium, LLC | 2 | $37 |
| Eisai Inc. | 2 | $36 |
| AbbVie | 1 | $34 |
| Aucta Pharmaceuticals, Inc. | 1 | $31 |
| Biogen | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Pyros Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Sarepta Therapeutics, Inc. | 1 | $18 |
| Aquestive Therapeutics, Inc. | 1 | $13 |
| PTC Therapeutics, Inc. | 1 | $13 |
| Biomarin Pharmaceutical Inc. | 1 | $12 |
How this compares
Too few neurology with special qualifications in child neurology providers in Idahoto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxtellar XrOxcarbazepine | 33 | $54,315 |
| XcopriCenobamate | 14 | $18,502 |
| Lacosamide | 12 | $3,442 |
| Levetiracetam ErLevetiracetam | 48 | $1,895 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $1,176 |
| Minocycline Hcl | 13 | $1,067 |
| Clonidine Hcl | 13 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $228 | $54,31533 claims |
| SK Life Science, Inc.Xcopri | $369 | $18,50214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology with special qualifications in child neurology providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other neurology with special qualifications in child neurology in Idaho Falls
- David BettisBoise$2K
- Lindsey FoyBoise$292
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.